H.C. Wainwright raised the firm’s price target on Praxis Precision to $120 from $105 and keeps a Buy rating on the shares. Praxis indicated it will be conducting an interim analysis of ulixacaltemide in Essential3 ahead of the full topline data readout in Q4, the analyst tells investors in a research note. The firm believes Praxis is taking appropriate steps to ensure success. It increased its probability of sucess to 55%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines Unveils Updated Corporate Presentation
- Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- Is PRAX a Buy, Before Earnings?
- Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
- PayPal, Kellanova upgraded: Wall Street’s top analyst calls